宜宾哪里有割双眼皮的宜宾割双眼皮要多久能好,宜宾开双眼皮有几种,宜宾去眼袋的方法,宜宾激光祛斑价格多少,宜宾哪家整形医院去眼袋专业,宜宾玻尿酸隆鼻大约多少钱,宜宾哪家整容医院激光祛斑好

GEORGETOWN, Del. (AP) — An 8-foot tall whipping post was removed from a Delaware county courthouse square Wednesday after activists said the post was a reminder of racial discrimination.The post outside the Sussex County Courthouse in Georgetown was removed after an hour and a half of excavation and put in storage unit with other historical artifacts.The Delaware Division of Historical and Cultural Affairs said the post was used to bind and whip people publicly for committing crimes up until 1952. However, Black people were disproportionately punished, according to the historical group.The group said the post was a “cold deadpan display” that didn’t “adequately account for the traumatic legacy it represents." 726

Get ready to pay a little more for Pampers, Charmin, Bounty, and Puffs.Procter & Gamble said on Tuesday that it was in the process of raising Pampers' prices in North America by 4 percent. P&G also began notifying retailers this week that it would increase the average prices of Bounty, Charmin, and Puffs by 5 percent.P&G is raising prices because commodity and transportation cost pressures are intensifying. The hikes to Bounty and Charmin will go into effect in late October, and Puffs will become more expensive beginning early next year.These products are significant sales drivers and market share leaders for P&G.Food companies, such as Coke, Boston Beer, Hershey, and Tyson Foods, have announced price increases in recent weeks, but P&G's move will serve as a test for how willing Americans are to pay up for big household brands. The strategy could leave the company vulnerable to low-cost competitors or pushback from retail partners. Walmart was P&G's biggest buyer in 2017, accounting for 16% of its billion in sales."There is uncertainty and will be volatility with these pricing moves. They will negatively impact consumption. We'll have to adjust as we go and as we learn," Chief Financial Officer Jon Moeller told analysts on Tuesday.Pampers is P&G's largest brand, with annual sales of above billion. Last year, Bounty had more than a 40% global share of the paper towel market, and Charmin had more than a 25% share of toilet paper sales.The company expects the price increases to weigh on sales at first, but turn around shortly after.Shipping costs have spiked as demand for goods accelerates and the United States faces a shortage of truck drivers. "The transportation market, particularly in the [United States], has presented us with some challenges," he added.P&G said the two factors were outsized components in the baby, fabric, and home care cost structure.Pulp, which is made from trees, is the primary ingredient in Bounty, Puffs and Charmin, and a major material in Pampers.Since 2016, market prices for hardwood pulp have risen 60% and 20% for softwood. P&G sources both types from the United States and Canada and uses them to make tissue papers and diapers.Growing global demand, particularly in China, and tight supply have pushed up prices, said Arnaud Franco, a senior analyst at the Pulp and Paper Products Council.The Trump administration has placed 10% on tariffs on Canadian paper and Canada responded by enacting 10 perecent levies on several paper products, including toilet paper. But Franco said tariffs were not currently impacting prices.If China, however, decided to put tariffs on market pulp, US producers could get hurt, Franco said.P&G's biggest competitor is feeling the pinch too. Kimberly-Clark, the maker of Kleenex, Scott, and Huggies, said commodity costs last quarter were a "a drag of 0 million...primarily due to higher pulp costs and, secondarily, inflation in other raw materials."Canadian company Kruger Products announced last week that it was raising tissue prices in that country beginning in October to "offset unprecedented and sustained cost increases on input materials and freight." Kruger said pulp costs were up 23 percent since last year.P&G is also raising prices as it looks for ways to recoup lower prices in other major categories.The company's operating profit margin last quarter shrank more than 2 percentage points from last year in part because it dropped price tags on brands including Gillette razors, Crest toothpaste, and Luvs diapers. 3585

FROSTPROOF, Fla. — The horrific act of violence done to an elderly beagle named “Max” is so severe it’s bringing tears to the volunteers tasked with saving his life.The beagle was found wandering December 11 near a home on the 500 block of Otto Polk Road in Frostproof, Florida. A good Samaritan cleaned Max’s wounds and then called Hardee Animal Rescue Team (HART), a nonprofit based in Wauchula, Florida to save his life.“Knife wounds on top of his neck and the big laceration across his back and a bullet on his head and a bullet on his ear,” said Leigh Sockalosky, the president of HART. “He got a blood transfusion yesterday. He was doing well but we did the blood transfusion to boost him up because the tissue, a lot of it dies and you have a lot of infection you are battling.” 808

From pond to pin! Rahm skips to a hole-in-one on No. 16 at #themasters pic.twitter.com/JNNPWgW9OP— The Masters (@TheMasters) November 10, 2020 150

Genetic testing company 23andMe has been given federal approval to sell at-home kits that test for three breast cancer gene mutations.This will be the first direct-to-consumer DNA test for these particular breast cancer gene mutations, the Food and Drug Administration said on Tuesday.A spokeswoman for 23andMe said the test for the three BRCA1/BRCA2 breast cancer gene mutations will be added "in the coming weeks" to the broader Health + Ancestry services, with no increase to the existing 9 cost.The test can only detect three out of more than 1,000 known BRCA mutations, according to the FDA. The BRCA1/BRCA2 hereditary mutations occur in about 2% of Ashkenazi Jewish women, but rarely occur in anyone else, the agency said in a press release."The test also does not provide information on a person's overall risk of developing any type of cancer," the FDA added.23sandMe already tests for genetic health risks for diseases like Parkinson's and Alzheimer's, along with wellness reports for things like lactose intolerance and saturated fat, and ancestral composition including Neanderthal ancestry.In 2013, the FDA ordered the company to stop sales of its home-testing kits, saying the Alphabet-backed company had failed to prove the validity of its product.Related: 23andMe gets funding for drug developmentAnne Wojcicki, who founded the company in 2006, called the FDA shutdown a "transformative moment" that prompted 23andMe to branch into drug development."Thank you to the FDA for hard work and progress on innovation," she tweeted on Tuesday.In 2015, 23andMe received approval from the FDA to test customers for whether they are carriers of certain disease-carrying genes that could be passed on to their children. In early 2017, the company received approval to issue genetic health risk reports.In September of last year, the company said it received 0 million in funding from Sequoia Capital to develop drugs based on user DNA.The-CNN-Wire? & ? 2018 Cable News Network, Inc., a Time Warner Company. All rights reserved. 2050